Jack Elands
Directeur Général chez Emergence Therapeutics AG
Profil
Jack Elands founded Amakem NV in 2009, where he worked as Chief Executive Officer & Director.
Dr. Elands also founded Emergence Therapeutics AG, where he is working as Chief Executive Officer from 2019.
Dr. Elands also currently works at BliNK Biomedical SAS, as Chairman & Chief Executive Officer.
Dr. Elands also formerly worked at Marion Merrell Dow, Inc., as Principal, Sidec AB, as Vice President-Business Development, and Silicos SA, as Chief Business Officer.
Dr. Elands received his undergraduate degree in 1985 from the University of Utrecht and doctorate degree in 1989 from University Medical Center of Utrecht.
Postes actifs de Jack Elands
| Sociétés | Poste | Début |
|---|---|---|
Emergence Therapeutics AG
 Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Directeur Général | 01/10/2019 |
BliNK Biomedical SAS
 BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Directeur Général | - |
Anciens postes connus de Jack Elands
| Sociétés | Poste | Fin |
|---|---|---|
| Marion Merrell Dow, Inc. | Corporate Officer/Principal | - |
Sidec AB
 Sidec AB BiotechnologyHealth Technology Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaborative research projects to the biopharmaceutical industry that reveal unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope. | Corporate Officer/Principal | - |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Fondateur | - |
Silicos SA
 Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Corporate Officer/Principal | - |
Formation de Jack Elands
| University of Utrecht | Undergraduate Degree |
| University Medical Center of Utrecht | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
Sidec AB
Sidec AB BiotechnologyHealth Technology Sidec studies molecular interactions in situ and in vitro using its proprietary technology Protein Tomography(TM). Sidec AB offers collaborative research projects to the biopharmaceutical industry that reveal unique information to prioritize the most promising therapeutic antibody and to locate the antibody binding epitope. | Health Technology |
Amakem NV
Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Health Services |
| Marion Merrell Dow, Inc. | Health Technology |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | Health Technology |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |